3 Penny Stocks To Watch Ahead Of Key Biotech Data $SELB $CLDX $SCYX

Penny Stocks To Watch With Presentations In November

Biotechnology stocks aren’t for the faint of heart. In fact, besides being incredibly speculative, this sector is built on volatility. Then, when you throw penny stocks into the equation, it’s likely that the volatility compounds. Sure, things like news and business updates can become catalysts. Additionally, the sector-wide excitement can be that tide to lift or drop all ships.

But seasoned biotech penny stock traders will tell you that data is the big one. Phase trials PDUFA data, and FDA presentations are just a few examples. When companies release info related to these and similar events, it could mean a wild day in the market. Of course, it goes without saying that the wildness can be seen on both up and downtrends. So you may be asking yourself, “Well, where can I find this info?”

There are a few places to find partial lists online, sure. But one clear way to do it is “use the news.” Biotech companies are some of the best at foreshadowing. They’ll put out news about a phase data presentation that will go on 4 months from the time of the news.

Average investors usually forget and by the time they remember, it’s when they see a stock going wild in the market. November appears to be a busy month for some biotech stocks and we’ll take a look at 3 that may have events to follow closely.

Biotech Penny Stocks To Watch: SCYNEXIS Inc. (SCYX)

This biotech company focuses on difficult to treat infections. SCYNEXIS Inc. (SCYX Stock Report) announced in late October that it will present data from its Phase 2b DOVE study, on November 2.

The study was for tracking the efficacy and safety of its oral ibrexafungerp compared to the standard of care fluconazole. The therapy is used to treat acute vulvovaginal candidiasis. Essentially it is caused by yeast.

Based on the fact that the event was held over the weekend, the market may signal its positive or negative reaction this week. New phase trial data are certainly something biotech investors look for.
Not only does it show progress in the company’s treatment pipeline but it also could indicate the likelihood of a commercially marketable product. Phase 2 is far from commercial-stage, however, positive or negative data can show how well the company’s drug was created.

 Biotech Penny Stocks To Watch: Celldex Therapeutics Inc. (CLDX)

Another one of the biotech penny stocks to watch this month, Celldex Therapeutics (CLDX Stock Report). The company reports the results of a Phase 1 study of its CDX-1140 alone and in combination with CDX-301. These are used to treat patients with advanced cancers.

The presentation will be at the Providence Cancer Institute on November 8. Furthermore, on November 9, the company will also present data on its CDX-527 treatment created to improve T Cell activation and anti-tumor activity. There’s also a pre-conference program session on November 6 that will highlight CDX-527.

Outside of these, the company will also present data at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. November 9 Celldex presents data on its CDX-0159. Needless to say, there’s a lot of presentations going on with the company and could be important to note as the first full week of November is underway.

Biotech Penny Stocks To Watch: Selecta Biosciences (SELB)

This biotechnology company has several abstracts set for presentations this month. Selecta Biosciences (SELB Stock Report) will present data on completed Phase 2 doses of its SEL-212 therapy to treat chronic refractory gout.

The 2019 American College of Rheumatology (ACR) Annual Meeting has become the site of these presentations and they’ll go on from November 8-13.

Additionally, the company reports its third-quarter results this week. On Friday, Selecta will present Q3 results before the market open. A conference call follows. With so much activity going on with Selecta, it’s no wonder why SELB stock has seen some activity in recent sessions.

Since October 24, the biotech penny stock has rallied from lows of $1.28 to as high as $1.61. Selecta firmly closed the week at $1.56 last Friday. What’s in store this week? We’ll see what happens leading up to key events in a few days.

* This article was originally published here